Single premedication dose of dexamethasone 20 mg IV before docetaxel administration

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 3, 2011, Pages 155-159

  Chouhan, Jyoti D ^a,b   Herrington, Jon D ^a,b,c  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

corticosteroid; dexamethasone; Docetaxel; edema; effusion; fluid retention; hypersensitivity; premedication

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; INFUSION FLUID; LORAZEPAM; OXYGEN; STEROID; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BACKACHE; BREAST CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUID RETENTION; FLUSHING; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INTRAVENOUS ADMINISTRATION; LUNG EDEMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OXYGEN THERAPY; PERIPHERAL EDEMA; PLEURA EFFUSION; PREMEDICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; EDEMA; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREMEDICATION; RETROSPECTIVE STUDIES; TAXOIDS; TEXAS;

EID: 80053336572     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210367950     Document Type: Article

References (11)

1. Sanofi-Aventis. Taxotere (docetaxel) package insert. Bridgewater, NJ: 2007.
2. Bergh M., Magnusson K., Nilsson JL, and Karlberg AT Contact allergenic activity of Tween 80 before and after air exposure. Contact Dermatitis 1997 ; 37: 9-18. (Pubitemid 27322990)
3. Coors EA, Seybold H., Merk HF, and Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 2005 ; 95: 593-599. (Pubitemid 43010488)
4. Lee C., Giano M., and Klaustermeyer WB Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009 ; 102: 179-187.
5. Semb KA, Aamdal S., and Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998 ; 16: 3426-3432. (Pubitemid 28481642)
6. Béhar A., Pujade-Lauraine E., Maurel A., et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997 ; 43: 653-658. (Pubitemid 27283577)
7. Schimmer BP, Paker KL Adrenocorticotropic hormone; adrenalcortical steroids and their synthetic analogs. In: Brunton LL, Lazo JS, and Paker KL (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York, NY: McGraw-Hill, 2006, p. 1587-1612.
8. Riva a, Fumoleau P., Roche H., et al. Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere (T) (abstract). Proc Am Soc Clin Oncol 1997 ; 16: 188a. Abstract 660.
9. Montoya ME, Markowitz AB, Klementich F., Palacio D. Docetaxel and fluid retention: use of single-dose dexamethasone (abstract). J Clin Oncol 2007 ; 25: 18S. Abstract 19635.
10. Tabernero J., Climent MA, Lluch A., et al. A multi-centre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004 ; 15: 1358-1365. (Pubitemid 39295024)
11. Gervais R., Ducolone A., Breton J., et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005 ; 16: 90-96. (Pubitemid 40124484)